Connect with us

Featured

ROKU Stock Price Hits Another Life Time High: Good News For Tech Stocks?

Joe Samuel

Published

on

roku stock price

Online media device manufacturer Roku Inc (ROKU Stock Chart) has been on a rollicking run in 2019, having risen significantly from the beginning of the year but on Tuesday this week, the stock rose again to hit its all-time high.

In 2019 alone, the stock has risen by as much as 271% as the company continued to add new customers and boosted revenues from advertising. However, could the latest surge be a signal for the next bull market in tech?

A Unique Model: Delivery Stocks Meet Technology

Technology has evolved over the years, and so have online websites and apps. Growing food delivery apps are the newest trend, expanding revenue generation in the food-service industry by 22% or more. And this new trend has created an even greater opportunity beyond food delivery alone!

One company, for example is ParcelPal (PTNYF) (PKG). It has created an on-demand marketplace where customers can shop for anything from food to clothes. There is no more waiting in line for lunch or rushing to the store after work to grab your clothes. With ParcelPal on-demand, customers simply shop from the app, choose the items they want, and pay. But with this has come mass expansion.

July 18 saw shares creep higher after the company released news of more growth in corporate footprint. The company continued its national rollout to Ontario, aiming at Canada’s financial capital, Toronto, as its initial launching point. ParcelPal is also actively looking to expand with new and existing partnerships within this region. These partnerships would add to the likes of deals already in place.

amazon stock price

ParcelPal (PTNYF) (PKG) has engaged in a work order contract with Amazon.com Inc. to fulfill package delivery on behalf of Amazon to residents in Metro Vancouver, British Columbia, Canada. ParcelPal (PTNYF) (PKG) has already seen exceptional growth in this division of the company since launch, growing over 115% week over week, delivering approximately 150,000 packages since mid-November.

The Company has been operating successfully in Vancouver, Calgary and Saskatoon and is now focusing its expansion plans in Ontario as part of its on-going strategy for Canada wide distribution. With new attention on tech, this could be well-timed growth for the company

Analyst’s Upgrade Roku Stock Price

One of the big triggers for ROKU stock price uptrend was the update from Crispidea. They are an equity research firm which upgraded the Roku stock price to buy from hold. It illustrated the reasons behind the change in their stance. The single most important reason is the company’s impressive revenue growth. If you take a closer look, you’d find that the company ended in 2018 with a 45% rise in annual revenues.

Additionally, Roku has also managed to grow advertising revenues. It ended 2018 with a year on year growth of 85% in its advertising revenues. In Q1 2019, the company’s revenues jumped by 51% from the year-ago period. The user base also ballooned by 40% to as many as 29 million active subscribers. More importantly, the streaming hours also skyrocketed. They hit 8.9 billion streams in Q1 2019. This reflects a rise of 74% from the year-ago period.

The other event that may have boosted Roku significantly was the Amazon (AMZN Stock Chart) Prime Day event this week. According to reports from Amazon, Roku devices and smart TVs equipped with Roku technology proved to be one of the highest-selling electronic items. The 32 inch Roku enabled TCL TV came in at number three among electronic item sales. Although it is true that the company doesn’t make a lot of money through licensed product, the platform gets to be showcased to a much larger group of people.

roku stock price
Disclaimer: MIDAM VENTURES LLC has been compensated $75,000 per month by a ParcelPal Technology, Inc. for a period beginning September 1, 2018 and ending February 1, 2019 to publicly disseminate information about (PTNYF/PKG) to publicly disseminate information about (PTNYF/PKG). Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to April 1, 2019. Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to May 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to June 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to July 1, 2019. We may buy or sell additional shares of (PTNYF/PKG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares. Click Here For Full Disclaimer

Continue Reading
Click to comment

Biotechnology

2 Biotech Stocks Turning Heads After Key Developments This Quarter

Joe Samuel

Published

on

biotech stocks to watch today

There are very few sectors in the stock market that have consistently produced winning trades. You might be able to count such sectors on one hand. Biotech is certainly among those sectors due to the emergence of highly innovative companies. These firms tend to create new avenues of creation to address unmet medical needs.

There are plenty of promising companies in the sector but it is necessary for an investor to do research thoroughly. It makes finding the best biotech stocks a bit easier. Though no one’s guaranteed a win, sifting out bad stocks is the key. One must watch the market closely to come across promising biotech stocks. Here is a look at two biotech stocks that are worth watching.

Biotech Stocks To Watch: Moleculin Biotech (MBRX)

The first biotech stock to consider is that of Moleculin Biotech Inc (NASDAQ:MBRX), which made some gains on Wednesday on the back of positive interim results for one of its products. The company, which is involved in manufacturing medicines meant for extremely resistant tumors, released data with regards to its acute myeloid leukaemia medicine annamycin.

top biotech stocks to buy

Moleculin revealed highly positive interim data from the Phase ½ clinical study of the medicine and naturally, it has resulted in a lot of excitement in the market with regards to the stock. The stock rose by as much as 2% on the back of the news in yesterday’s trading session. It is one of the key biotech stocks to keep an eye on over the coming days.

Biotech Stocks To Watch: Eyepoint Pharmaceuticals (EYPT)

The other biotech stock that has recorded impressive gains on the market today is the Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) stock. On Wednesday, the company announced an important deal with regard to dexamethasone intraocular suspension 9% (DEXYCU). Eyepoint announced that it has managed to reach an agreement with one of the biggest players in the U.S. integrated delivery systems.

[Read More] 3 Pharma Stocks To Watch In December 2019

The deal is for two years and the other party is going to offer DEXYCU in its aforesaid systems. It is a major boost for Eyepoint and it has resulted in 5% to close at $1.54 in Wednesday’s trading session.

best biotech stocks to watch today

Continue Reading

Featured

Stock Price Newsletter – December 6, 2019

Joe Samuel

Published

on

stock price newsletter

2 Biotech Stocks to Watch As The Sector Hits New High

The biotech sector has thrown plenty of winners over the course of the last decade or so and if experts are to be believed then it is going to continued to do so for the foreseeable future. Great advancements are being made in the biotech industry and many companies are working on a highly advanced product.

Continue Reading


Is It Time To Buy Or Sell Netflix; Streaming Wars Heat Up

The streaming wars have commenced this month with the launch of Disney Plus and Apple TV+. Many more services are going to be launched over the coming months and the sole purpose of these services is to topple the biggest name in the streaming services, Netflix Inc (NASDAQ:NFLX). The streaming giant has had a hard time this year, due to disappointing subscriber growth.

Click To Read More


Is ROKU Stock a Buy Or Hold on Disney, Apple & Streaming TV Growth?

The stock suffered a slump following its Q3 2019 financial results but since then it has regained much of the losses. While it is true that the losses widened from the year-ago period, experts believe that Roku is a stock that could have long term growth potential.

See For Yourself

Continue Reading

Biotechnology

2 Biotech Stocks to Watch As The Sector Hits New High

Joe Samuel

Published

on

best biotechnology stocks to buy sell

The biotech sector has thrown plenty of winners over the course of the last decade or so and if experts are to be believed then it is going to continued to do so for the foreseeable future. Great advancements are being made in the biotech industry and many companies are working on a highly advanced product.

In such a situation, it is imperative for an intelligent investor to look for companies worth investing in. One should watch the latest developments in the sector and track specific companies closely. Here is a look at two biotech stocks that are worth watching.

Neoleukin Therapeutics

top biotech stocks to watch list

The first biotech stock to watch is that of Neoleukin Therapeutics Inc (NLTX), which has managed to gain significantly over the past two weeks. On November 13, the company released its third-quarter results and since then it has rocketed by as much as 75%. The Canadian company made a loss of $59.1 million in the quarter, which worked out to $2.26 per share.

The company is a biopharmaceutical company that is involved in immunotherapies using de novo protein design technology. The company’s lead product candidate is NL-201, which is an amalgamation of both IL-2 and IL-15 and helps in removing alpha receptor binding.

Verastem

healthcare stocks to buy now

The other biotech stock that is worth watching is Verastem Inc (NASDAQ:VSTM). It made significant gains over the past week. On Monday, the company announced that it has submitted a Marketing Authorization Application for its product COPIKTRA to the European Medicines Agency.

COPIKTRA is a phosphoinositide 3-kinase. It’s meant for patients suffering from refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL).

The company is seeking approval for the same in the European market. Verastem stated that it has seen significant improvement in patients who used the product. The stock rocketed by as much as 60% after the news broke and remains one of the stocks to watch this week.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com